AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03635957 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Subjects will also take folic acid 1 mg orally every day beginning at Week -4 (the start of MTX) and continuing until prior to the Week 52 Visit.
Study NCT03960957 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment of glabellar facial lines with placebo
Study NCT00829400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: Brain Fitness, Insight, and Aristotle Cognitive Remediation Software Suites Targeting 100 hours of training
Study NCT00829400 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nintendo Brain Age
Description: Brain Age 2 Software Nintendo DS Portable for home or office use Targeting 100 hours of training
Study NCT05058105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FL058 Placebo and Meropenem 2000m（ IV 120min）
Description: D1 qd;~D2\~ D8 q8h;~D9 qd
Study NCT05058105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FL058 1000mg and Meropenem 2000mg （ IV 180min）
Description: D1 qd;~D2\~ D8 q8h;~D9 qd
Study NCT05058105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FL058 Placebo and Meropenem 2000m（ IV 180min）
Description: D1 qd;~D2\~ D8 q8h;~D9 qd
Study NCT05058105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FL058 2000mg and Meropenem 2000mg（ IV 180min）
Description: D1 qd;~D2\~ D8 q8h;~D9 qd
Study NCT05058105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FL058 Placebo and Meropenem 2000mg（ IV 180min）
Description: D1 qd;~D2\~ D8 q8h;~D9 qd
Study NCT03630198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid with lidocaine
Description: Intralesional corticosteroid injection
Study NCT03630198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid with normal saline
Description: Intralesional corticosteroid injection
Study NCT01563120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: metformin up to 2550mg per day.
Study NCT01563120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glybenclamide
Description: glybenclamide up to 20mg per day.
Study NCT03938220 — intervention group
Intervention type: DEVICE
Intervention: Electrical Cardiometry
Description: Electrical cardiometry (EC) measurements: by the ICON_ hemodynamic monitor (ICON Cardiotronics, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3, Serial no: 1725303). Four sensors of EC will be applied (1st: 5 cm above the base of the neck, 2nd: on the base of neck, 3rd: lower thorax at the level of the xiphoid and 4th: 5 cm below the 3rd electrode at the level of anterior axillary line). The ICON continuously displays HR, SV and CO.
Study NCT04270162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training 1
Description: For inspirometer, the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale (exhale) normally until you run out of air. And after that, inhale (inspire) slowly as much as possible. This maximum value will be taken as an indicative parameter of its maximum inspiratory capacity and 50 and 80% of that value will be determined so that the participant performs 1 set of 10 repetitions at 50% of their maximum value, 2 sets of 10 repetitions at 60% of its maximum capacity and ends with 1 series at 80% of its maximum capacity.~It is highlighted that in each series before finishing and without stopping to rest, the participant must do 5 repetitions at 100% maximum capacity.~In addition, the respiratory exercises that will be carried out by the 3 intervention groups.
Study NCT04270162 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory muscle training 2
Description: Training of respiratory muscles under the protocol of conventional use. Which is that the participant sits and holds the device. Then put the mouthpiece of the inspirometer in the mouth. Be sure to make a good seal on the mouthpiece with your lips. And exhale (exhale) normally until you run out of air. And after that, inhale (inspire) slowly as much as possible. Repeat 10 times and use these indications for 3 sets.~In addition, participants must perform different breathing exercises that are identical for the 3 intervention groups.
Study NCT04270162 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory muscle training 3
Description: The same exercises that apply to the participants of experimental group 1 and 2 will be performed. The only difference is that the participants of this group do not perform exercises with inspirometer.
Study NCT03332719 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Study NCT03332719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etanercept
Study NCT03566615 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: water
Description: using water instead of traditional air insufflation to help insertion
Study NCT03332719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Study NCT03332719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study NCT02537262 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: carbohydrate beverage
Description: Carbohydrate group drinks carbohydrate beverage 400ml(9PM\~MN) the day before the surgery and 200ml three hours before the surgery.
Study NCT02537262 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: NPO(None Per Oral)
Description: NPO group does not drink any water from the MN before the surgery.
Study NCT01691014 — intervention group
Intervention type: OTHER
Intervention: non-interventional study
Description: Study with 4 arms/groups with 36 patients per group. In total 144 patients.
Study NCT01129037 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Goal directed fluid management based on continuous monitoring of stroke volume
Description: Baseline SV measurement, repeated volume loading (VL) with aliquots of 250 ml HES until SV increased \< 10% in response to receding VL: SV is optimized, no further VL required.
Study NCT03598205 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: DIABEC plus intravitreal dexamethazone
Description: Patients with diabetic macular edema undergoing to intravitreal dexamethazone will be randomized to curcumin formulation (DIABEC)
Study NCT02387801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC
Study NCT04072367 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NeVa Stent Retrievers
Description: thrombus removal
Study NCT04072367 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Solitaire Stent Retrievers
Description: thrombus removal
Study NCT01219036 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Budesonide (directly observed)
Description: Budesonide 1600 micrograms daily directly observed for 7 days
Study NCT03281330 — intervention group
Intervention type: BEHAVIORAL
Intervention: auditory cues and music during walking
Description: the effect of different conditions of auditory cueing and music on walking quality and perceived fatigue in persons with multiple sclerosis compared to healthy controls
Study NCT01305850 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients in the control group will administer antihypertensive agents, except angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone. Dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
Study NCT01305850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: Patients with hypertension will take fixed-dose 150 mg aliskiren per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blocker and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
Study NCT01305850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren plus Losartan
Description: Patients with hypertension will take fixed-dose 150 mg aliskiren + 50 mg losartan per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
Study NCT01305850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril plus Losartan
Description: Patients with hypertension will take fixed-dose 20 mg enalapril + 50 mg losartan per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
Study NCT02924766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Participants will receive apalutamide 240 mg (4\*60 mg) once daily orally.
Study NCT02924766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Participants will receive 1000 mg (4\*250mg) once daily.
Study NCT02924766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will receive 10 mg (1\*5 mg twice daily).
Study NCT02231970 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic sleeve gastroplasty
Description: To perform endoluminal gastric volume reduction by the Endoscopic sleeve gastroplasty
Study NCT03407976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib oral daily at starting dose 1, Dose Level 2 or Dose Level 3 in phase I, and then whichever is the maximum tolerated dosage will be used for all Phase II patients.
Study NCT03407976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg Q3 weeks IV
Study NCT03188003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Movement Techniques based on mobilization
Description: 10 sessions will be held twice a week, with each session taking an average of 50 minutes.
Study NCT03188003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Movement Techniques based on stabilization
Description: 10 sessions will be held twice a week, with each session taking an average of 50 minutes.
Study NCT03725566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Recombinant humanized anti-VEGF monoclonal antibody injection 0.625mg/1.25mg/2.0mg/2.5mg by intravitreous injection,day 1 in the first month;
Study NCT03444246 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iodine free diet group
Description: 120 patients with hyperthyroidism relapsed after new diagnosis or treatment were enrolled. They were randomly divided into iodine free diet group and normal iodine diet group. The two groups were treated with routine antithyroid drugs, followed up for 6 months.
Study NCT03444246 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Normal iodine diet group
Description: 120 patients with hyperthyroidism relapsed after new diagnosis or treatment were enrolled. They were randomly divided into iodine free diet group and normal iodine diet group. The two groups were treated with routine antithyroid drugs, followed up for 6 months.
Study NCT03444246 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Normal iodine diet group
Description: 120 patients with hyperthyroidism relapsed after new diagnosis or treatment were enrolled. They were randomly divided into iodine free diet group and normal iodine diet group. The two groups were treated with routine antithyroid drugs, followed up for 6 months.
Study NCT05972668 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone Apps
Description: The intervention group downloaded the asthma smartphone app, and followed up monthly via phone calls and clinic visits
Study NCT04009252 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3D Model Education
Description: A 3D model of the patients ankle fracture will be printed and used as a teaching tool to discuss long-term outcomes and potential complications.
Study NCT02390323 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Sympathetic Block
Description: A lumbar sympathetic block is an injection in the middle of the lower back, toward the left or right side. The lumbar sympathetic nerves are a small bundle of nerves that carries sympathetic nerve signals from the lower extremities. In some instances, certain injuries to the lower extremities can cause a burning, unusual pain called complex regional pain syndrome or reflex sympathetic dystrophy. Injecting a small amount of local anesthetic on the lumbar sympathetic nerves can identify whether or not this pain is carried by the sympathetic nervous system.
Study NCT01389401 — intervention group
Intervention type: DRUG
Intervention: omeprazole
Description: omeprazole 40 mg twice a day for 16 weeks; dietary and lifestyle changes
Study NCT02390323 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skin conductance algesimeter
Description: The real-time changes in skin conductance indices can be monitored at the skin level, by use of non-invasive electrodes attached to the skin (similar to EKG electrodes) connected to the skin conductance algesimeter. A computer program analyzes the data and produces a real-time graphic and numeric data demonstrating the skin conductance response. The initiation of successful sympathetic blockade can cause rapid cessation of the skin sympathetic activity that leads to a decrease in skin conductance within seconds.
Study NCT02299128 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Physical Therapy Treatment
Study NCT00198861 — intervention group
Intervention type: OTHER
Intervention: Injection and Non-Injection Drug Users
Description: (1) the degree to which specific executive dysfunctions predispose heroin and cocaine users to high-risk injection practices or sex behaviors, and (2) whether observed relationship between executive dysfunction and HIV-risk behaviors can be understood independent of levels of drug -taking frequency, or whether the observed data are more consistent with complex patterns of interdependency between executive dysfunction, drug-taking frequency, and HIV-risk-behaviors.
Study NCT02082223 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interventions to improve preop QOL/resilience deficits
Description: Identify patients' and patients' care givers quality of life/resilience deficits and supply information and resources prior to undergoing complex GI surgery.
Study NCT02413736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib 400 mg/day
Study NCT02299128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy Treatment
Study NCT02014480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Umeclidinium 62.5 mcg
Description: Umeclidinium 62.5 mcg once daily in the morning via NDPI.
Study NCT02014480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vilanterol 25 mcg
Description: Vilanterol 25 mcg once daily in the morning via NDPI.
Study NCT02014480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Umeclidinium/Vilanterol 62.5/25 mcg
Description: Umeclidinium/Vilanterol 62.5/25 mcg once daily in the morning via NDPI.
Study NCT03114124 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIFI Catheter
Description: Multielectrode Catheter: standard ablation catheter that has the ability to record low and high frequency signals with high fidelity
Study NCT03114124 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Ablation Catheter
Description: Standard of care for patients with certain cardiac arrhythmias.
Study NCT01616940 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Peer Intervention
Description: Eight 30-60 minute educational sessions with peer will occur in-person bi-weekly once participant is randomized to intervention:~* Introduction and Assessment~* HIV Transmission \& Viral Life Cycle~* Effective Communication and Self-Advocacy~* Understanding Lab Values~* HIV Medications~* Drug Resistance \& Adherence, and Understanding \& Managing Side Effects~* Disclosure and Stigma~* Harm \& Risk Reduction~Weekly check-ins will be by phone or in-person over 12 months. Check-in questions/tasks:~* Are any services needed?~* Have referrals or appointments been made?~* Does patient need accompaniment to a visit?~* Connect patient with services as needed.~* Appointment reminders.~* Overall well-being?~* Schedule next peer contact.
Study NCT04216940 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mechanical preparation of root canal system
Description: Assess the pain intensity in a two-visit treatment of molars with irreversible pulpitis after instrumentation with two different rotary Nickle Titanium systems
Study NCT00715364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTx™-265: rhCG, then rEPO
Description: * rhCG 385 µg, SC, on Day 1, 3, and 5 of study participation, then~* rEPO 30,000 IU, IV, on Day 7, 8, and 9 of study participation
Study NCT00715364 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: * Saline SC, on Day 1, 3, and 5 of study participation, then~* Saline IV, on Day 7, 8, and 9 of study participation
Study NCT01143051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epinephrine inhalation aerosol
Description: Single dose 220 mcg/inhalation, 10 inhalations
Study NCT01143051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinephrine inhalation aerosol
Description: HFA propelled epinephrine inhalation aerosol, 125 mcg/inhalation, 10 inhalations
Study NCT01143051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinephrine inhalation aerosol
Description: HFA propelled epinephrine inhalation aerosol, 160 mcg/inhalation, 10 inhalations
Study NCT04371822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SnPP Protoporphyrin plus Sunlight exposure
Description: SnPP Protoporphyrin plus Sunlight exposure
Study NCT04371822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SnPP Protoporphyrin plus Sunlight exposure
Description: SnPP Protoporphyrin and Sunlight exposure
Study NCT04371822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfonatoporphyrin(TPPS) plus Sunlight exposure.
Description: Sulfonatoporphyrin(TPPS) plus Sunlight exposure.
Study NCT04371822 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: No Intervention
Study NCT00856141 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: phacoemulsifcation
Description: A sensor (Blumenthal cannula) connected to a transducer, a signal amplifier, an IOP recording device, and a display unit
Study NCT00856141 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: phacoemulsifcation
Description: A sensor (Blumenthal cannula) connected to a transducer, a signal amplifier, an IOP recording device, and a display unit
Study NCT02186288 — intervention group
Intervention type: OTHER
Intervention: High-flow nasal cannula oxygen
Study NCT01958073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conjugated Estrogen Vaginal Cream
Study NCT01958073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Ring
Study NCT01958073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02881918 — intervention group
Intervention type: OTHER
Intervention: Blood sample
Description: Blood sample with 6 tube of blood (40 mL), after diagnosis and before any specific anticancer treatment
Study NCT00474266 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612 (Nimenrix)
Description: Single dose intramuscular injection
Study NCT00474266 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Priorix-Tetra
Description: 2-dose subcutaneous injection
Study NCT00474266 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Priorix-Tetra
Description: 2-dose subcutaneous injection
Study NCT00474266 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningitec
Description: Single dose intramuscular injection
Study NCT01476033 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: nutraceutical group
Description: 6 capsules of supplement or placebo for 8wk
Study NCT03513055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nurse inject premixed insulin
Description: nurse inject premixed insulin，coaching in the injection technique
Study NCT03951220 — intervention group
Intervention type: OTHER
Intervention: Diffusion Weighted Magnetic Resonance Imaging (DWMRI)
Description: Using the expertise of the Oxford Centre For Clinical Magnetic Resonance Research (OCMR) for imaging protocol development, and the new Fine Structural Analysis (FSA, Osteotronix Ltd, formerly Acuitas Medical) bone density quantification MRI method (Rafferty et al 2016), we will test a single protocol which combines three emerging experimental imaging sequences into a simple, non-invasive whole body imaging protocol to quantify disease burden and bone disease. To our knowledge, this has never been done before; if shown to be feasible, such a method would have two important applications: to precisely guide commissioned therapies in the clinic, so improving patient management; and as an exciting, novel research tool for the longitudinal combined assessment of tumour burden and cancer-induced bone disease in response to therapy.
Study NCT03951220 — intervention group
Intervention type: OTHER
Intervention: DXA scan
Description: Used to assess bone density